The Journal of
Clinical Psychiatry

Schizophrenia/Schizoaffective Disorders

Letter to the Editor November 15, 2007

Reply to Aripiprazole and Perphenazine: No Difference

John M. Kane; Herbert Y. Meltzer; William H. Carson, Jr.; Robert D. McQuade; Ronald N. Marcus; Raymond Sanchez

J Clin Psychiatry 2007;68(11):1813-1814

Article Abstract

Letter to the Editor

Download Free PDF

Save Save

Cite

Advertisement
GAM ID: sidebar-top

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Advertisement
GAM ID: sidebar-bottom

Vol 85 • 2024 • Number 3

Read the Current Issue

Editorial

Focus on Women’s Mental Health: Twenty Years and Counting

Original Research

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

Commentary

Can Our Collective Experiences As Clinicians Improve Mental Health Care?

Original Research

Prescription Opioid Use Disorder in US Adults Reporting Prescription Opioid Use

Original Research

Symptomatic Disorders Comorbid with Borderline Personality Disorder Over Time

Original Research

Aripiprazole Lauroxil Initiation Regimens

View current Issue

Letter to the Editor

Smartphone Applications: Therapy at Your Fingertips

August 20, 2024

The authors discuss the advancements in smartphone applications for psychiatry, as well as some of the risks.

Vania Modesto-Lowe, Sofia Adams, Amanda Rossi

Letter to the Editor

Zeroing in on Xylazine

August 15, 2024

The authors discuss the need to raise awareness among US public and health care professionals about xylazine due to its infiltration into the illicit drug supply.

Jasleen Kaur, Megan Nosol, Vania Modesto-Lowe

Letter to the Editor

A Mnemonic for Psychiatric History of Presenting Illness

July 18, 2024

In this letter to the editor, the author presents a mnemonic created to help clinicians obtain a psychiatric history.

Abdulsamad A. Aljeshi

Reply to Aripiprazole and Perphenazine: No Difference

Read the Current Issue

Focus on Women’s Mental Health: Twenty Years and Counting

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

Can Our Collective Experiences As Clinicians Improve Mental Health Care?

Prescription Opioid Use Disorder in US Adults Reporting Prescription Opioid Use

Symptomatic Disorders Comorbid with Borderline Personality Disorder Over Time

Aripiprazole Lauroxil Initiation Regimens

ELSEWHERE:

FOLLOW US:

Reply to Aripiprazole and Perphenazine: No Difference

Read the Current Issue

Focus on Women’s Mental Health: Twenty Years and Counting

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

Can Our Collective Experiences As Clinicians Improve Mental Health Care?

Prescription Opioid Use Disorder in US Adults Reporting Prescription Opioid Use

Symptomatic Disorders Comorbid with Borderline Personality Disorder Over Time

Aripiprazole Lauroxil Initiation Regimens

Related Articles

Smartphone Applications: Therapy at Your Fingertips

Zeroing in on Xylazine

A Mnemonic for Psychiatric History of Presenting Illness

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles